吉非替尼按時(shí)辰給藥的藥理作用特點(diǎn)及其機(jī)制研究
發(fā)布時(shí)間：2018-09-03 14:08
【摘要】：目的初步探討吉非替尼按時(shí)辰給藥荷瘤小鼠的藥理作用特點(diǎn)及其作用機(jī)制。 方法 1.建立肺癌小鼠模型并分組：利用C57BL/6小鼠建立lewis肺癌小鼠模型,將荷瘤小鼠隨機(jī)分成13組(n=10),即A-F六個(gè)實(shí)驗(yàn)組、a-f六個(gè)空白組和對(duì)照組；A-F實(shí)驗(yàn)組分別在8：00、12：00、16：00、20：00、24：00、次日4：00以灌胃方式給藥(100m·kg-1),空白組和對(duì)照組給予相同劑量的含有5%羧甲基纖維素鈉的蒸餾水。 2.日常指標(biāo)的測(cè)定：連續(xù)給藥時(shí)間21天,每天觀察并記錄各組小鼠生存狀態(tài)及出現(xiàn)肛周紅腫的小鼠數(shù)量,每三天測(cè)定一次小鼠腫瘤體積,三周后在相應(yīng)的時(shí)間進(jìn)行眼眶取血并脫臼處死小鼠,剝離腫瘤并稱量瘤重,計(jì)算抑瘤率。 3.血常規(guī)檢測(cè)：各組每只荷瘤小鼠取50μl血液進(jìn)行血常規(guī)檢測(cè)。 4.腫瘤組織和皮膚組織的觀察：對(duì)剝離的腫瘤同時(shí)進(jìn)行病理學(xué)分析以及掃描電鏡分析,同時(shí)對(duì)部分皮膚組織進(jìn)行掃描電鏡觀察。 5.細(xì)胞因子的測(cè)定：應(yīng)用ELISA技術(shù)(按照美國(guó)Biolegend公司試劑盒說(shuō)明書(shū)的要求)測(cè)定不同組的小鼠血液中細(xì)胞因子IL-6. IL-2和TNF-a水平。 6.基因表達(dá)的測(cè)定：應(yīng)用RT-PCR技術(shù)測(cè)定腫瘤組織中EGFR、MMP-9、ABCG2和P35基因表達(dá)。 結(jié)果 1.吉非替尼對(duì)小鼠的生存質(zhì)量有一定的影響,A、B、F組的小鼠精神狀態(tài)和身體狀況比C、D、E組好,A組和F組荷瘤小鼠的肛周紅腫率較其它實(shí)驗(yàn)組低。 2.吉非替尼可以明顯抑制腫瘤的增長(zhǎng),在所有的實(shí)驗(yàn)組中,A組荷瘤小鼠的腫瘤體積增長(zhǎng)最緩慢(P0.05),A組的抑瘤率最高,C組最低(44.12%vs14.15%,x2=36.00,P=0.000),F組次之；病理學(xué)分析和掃描電鏡分析顯示A組和F組腫瘤組織壞死最嚴(yán)重,該組的上皮細(xì)胞損傷程度較其它實(shí)驗(yàn)組輕。 3.血常規(guī)分析各組白細(xì)胞、紅細(xì)胞、血紅蛋白、中性粒細(xì)胞差異沒(méi)有統(tǒng)計(jì)學(xué)意義(P0.05)；實(shí)驗(yàn)組小鼠血清中的IL-6、IL-2和TNF-a含量升高。A組和F組血清中的IL-6、IL-2和TNF-α水平最接近對(duì)照組的水平,C組和D組含量最高,差異顯著(P0.05)。 4.時(shí)辰給藥荷瘤小鼠對(duì)EGFR基因表達(dá)影響不同,A組EGFR表達(dá)最低,C、D組EGFR基因表達(dá)相對(duì)較高,差異有統(tǒng)計(jì)學(xué)意義(P0.05)�？瞻捉M間EGFR基因表達(dá)呈節(jié)律性變化,12:00左右時(shí)表達(dá)最高,20：00左右時(shí)EGFR表達(dá)最低。各實(shí)驗(yàn)組中MMP-9、ABCG2和P53基因表達(dá)有顯著性差異,C組和D組表達(dá)最高,A組表達(dá)最低(P0.05)。結(jié)論 1.吉非替尼在荷瘤小鼠上的抗腫瘤活性和毒副作用存在時(shí)辰節(jié)律性,明期早期(8：00)和暗期晚期(4：00)的抗腫瘤活性較強(qiáng),對(duì)小鼠的毒副作用相對(duì)較低。 2.吉非替尼藥理學(xué)作用特點(diǎn)呈時(shí)辰節(jié)律性變化,其機(jī)制可能與荷瘤小鼠體內(nèi)的EGFR呈節(jié)律性變化有關(guān)；應(yīng)用吉非替尼時(shí),應(yīng)考慮時(shí)間因素的影響。
[Abstract]:Objective to investigate the pharmacological characteristics and mechanism of gifitinib in mice with tumor-bearing drugs. Method 1. To establish lung cancer mice model and group: the lewis lung cancer mice model was established by C57BL/6 mice. The tumor bearing mice were randomly divided into 13 groups, namely A-F six experimental groups, a-f six blank group and control group. A-F experimental group was given orally at 8: 00 at 12: 00 to 16: 00 at 20: 00: 24: 00, by gavage at 4:00 the next day (100m kg-1). The blank group and the control group were given the same dose of distilled water containing 5% carboxymethyl cellulose sodium. 2. Measurement of daily indexes: continuous administration for 21 days, observed and recorded the survival status and the number of mice with perianal redness and swelling in each group, and measured the tumor volume of mice every three days. Three weeks later, blood was taken from orbit and dislocated mice were killed at the corresponding time, tumor was stripped and weighed, and tumor inhibition rate was calculated. Blood routine examination: 50 渭 l blood samples were taken from each tumor-bearing mouse in each group. 4. 4. Observation of tumor tissue and skin tissue: pathological analysis and scanning electron microscope analysis of exfoliated tumor were carried out simultaneously, and some skin tissues were observed by scanning electron microscope at the same time. Determination of cytokines: determination of cytokine IL-6. in blood of different groups of mice by ELISA technique (as required by Biolegend kit specification) IL-2 and TNF-a levels. Detection of gene expression: RT-PCR technique was used to detect the expression of EGFR,MMP-9,ABCG2 and P35 genes in tumor tissues. Result 1. Gefitinib had a certain effect on the quality of life of mice. The mental state and physical condition of the BF group were lower than those of the other experimental groups. 2. The rate of perianal red swelling in group A and group F was lower than that in group A and F. Gefitinib could significantly inhibit tumor growth. In all the experimental groups, the tumor volume of group A was the slowest (P0.05), the inhibition rate of group C was the highest (44.12 vs 14.15x36.00 P0. 000) and that of group F was the lowest. Pathological analysis and scanning electron microscope analysis showed that tumor tissue necrosis was the most serious in group A and group F, and the degree of epithelial cell injury in group A was less than that in other experimental groups (3.3%). There was no significant difference in white blood cell, erythrocyte, hemoglobin, neutrophil in each group by blood routine analysis (P0.05). The levels of IL-6,IL-2 and TNF- 偽 in serum of group A and F were the highest in group C and group D (P0.05). Effect of time administration on the expression of EGFR gene in tumor-bearing mice the expression of EGFR gene in the lowest EGFR expression group (P 0.05) was significantly higher than that in the control group (P 0.05). There was a rhythmic change of EGFR gene expression in the blank group. The highest expression of EGFR gene was observed at about 12: 00 and the lowest at about 20: 00. There was significant difference in the expression of MMP-9,ABCG2 and p53 gene in each experimental group. The expression of MMP-9,ABCG2 and p53 gene was the lowest in group C and group D (P0.05). Conclusion 1. The antitumor activity and side effects of Gifitinib in tumor-bearing mice were rhythmic, and the antitumor activity in early stage (8:00) and late stage (4:00) was stronger, and the toxicity and side effect of gifitinib on mice was relatively low. 2. The pharmacological characteristics of gefitinib were time-rhythmic, and its mechanism might be related to the rhythmic change of EGFR in tumor-bearing mice, and the effect of time should be taken into account when gifetini was used.
【學(xué)位授予單位】：青島大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2014
【分類號(hào)】：R965
本文編號(hào)：2220197
[Abstract]:Objective to investigate the pharmacological characteristics and mechanism of gifitinib in mice with tumor-bearing drugs. Method 1. To establish lung cancer mice model and group: the lewis lung cancer mice model was established by C57BL/6 mice. The tumor bearing mice were randomly divided into 13 groups, namely A-F six experimental groups, a-f six blank group and control group. A-F experimental group was given orally at 8: 00 at 12: 00 to 16: 00 at 20: 00: 24: 00, by gavage at 4:00 the next day (100m kg-1). The blank group and the control group were given the same dose of distilled water containing 5% carboxymethyl cellulose sodium. 2. Measurement of daily indexes: continuous administration for 21 days, observed and recorded the survival status and the number of mice with perianal redness and swelling in each group, and measured the tumor volume of mice every three days. Three weeks later, blood was taken from orbit and dislocated mice were killed at the corresponding time, tumor was stripped and weighed, and tumor inhibition rate was calculated. Blood routine examination: 50 渭 l blood samples were taken from each tumor-bearing mouse in each group. 4. 4. Observation of tumor tissue and skin tissue: pathological analysis and scanning electron microscope analysis of exfoliated tumor were carried out simultaneously, and some skin tissues were observed by scanning electron microscope at the same time. Determination of cytokines: determination of cytokine IL-6. in blood of different groups of mice by ELISA technique (as required by Biolegend kit specification) IL-2 and TNF-a levels. Detection of gene expression: RT-PCR technique was used to detect the expression of EGFR,MMP-9,ABCG2 and P35 genes in tumor tissues. Result 1. Gefitinib had a certain effect on the quality of life of mice. The mental state and physical condition of the BF group were lower than those of the other experimental groups. 2. The rate of perianal red swelling in group A and group F was lower than that in group A and F. Gefitinib could significantly inhibit tumor growth. In all the experimental groups, the tumor volume of group A was the slowest (P0.05), the inhibition rate of group C was the highest (44.12 vs 14.15x36.00 P0. 000) and that of group F was the lowest. Pathological analysis and scanning electron microscope analysis showed that tumor tissue necrosis was the most serious in group A and group F, and the degree of epithelial cell injury in group A was less than that in other experimental groups (3.3%). There was no significant difference in white blood cell, erythrocyte, hemoglobin, neutrophil in each group by blood routine analysis (P0.05). The levels of IL-6,IL-2 and TNF- 偽 in serum of group A and F were the highest in group C and group D (P0.05). Effect of time administration on the expression of EGFR gene in tumor-bearing mice the expression of EGFR gene in the lowest EGFR expression group (P 0.05) was significantly higher than that in the control group (P 0.05). There was a rhythmic change of EGFR gene expression in the blank group. The highest expression of EGFR gene was observed at about 12: 00 and the lowest at about 20: 00. There was significant difference in the expression of MMP-9,ABCG2 and p53 gene in each experimental group. The expression of MMP-9,ABCG2 and p53 gene was the lowest in group C and group D (P0.05). Conclusion 1. The antitumor activity and side effects of Gifitinib in tumor-bearing mice were rhythmic, and the antitumor activity in early stage (8:00) and late stage (4:00) was stronger, and the toxicity and side effect of gifitinib on mice was relatively low. 2. The pharmacological characteristics of gefitinib were time-rhythmic, and its mechanism might be related to the rhythmic change of EGFR in tumor-bearing mice, and the effect of time should be taken into account when gifetini was used.
【學(xué)位授予單位】：青島大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2014
【分類號(hào)】：R965
【參考文獻(xiàn)】
相關(guān)期刊論文 前10條
1 杜志明;吳志誠(chéng);江濤;賀方興;江柏青;;VEGF-C和ABCG2在非小細(xì)胞肺癌中的表達(dá)及意義[J];贛南醫(yī)學(xué)院學(xué)報(bào);2010年02期
2 張靖;馬虎;韓靜;李雪濤;陳正堂;;ABCG2在非小細(xì)胞肺癌厄洛替尼耐藥中的作用[J];第三軍醫(yī)大學(xué)學(xué)報(bào);2014年10期
3 張宇飛;郭麗;趙峰;姜曉玲;穆德廣;徐興祥;戚好文;;ABCG2在肺癌中的表達(dá)及意義[J];解放軍醫(yī)學(xué)雜志;2007年09期
4 亓梅;趙慧;王翠萍;;P53與肺癌診斷治療研究進(jìn)展[J];臨床肺科雜志;2007年11期
5 韓雪;戴廣海;;胃癌中EGFR相關(guān)研究及意義[J];臨床腫瘤學(xué)雜志;2010年02期
6 喬建兵;陳文萍;;比較吉非替尼與化療一線治療晚期非小細(xì)胞肺癌的Meta分析[J];臨床腫瘤學(xué)雜志;2013年05期
7 周守兵;蔣華;李文娟;房新建;;培美曲塞時(shí)辰給藥治療肺腺癌裸鼠移植瘤的療效[J];實(shí)用醫(yī)學(xué)雜志;2012年14期
8 柯立;徐美青;魏大中;馬冬春;;非小細(xì)胞肺癌中S100A2和p53蛋白的表達(dá)[J];安徽醫(yī)科大學(xué)學(xué)報(bào);2010年04期
9 張曉梅;鐘建明;湯敏中;張曉光;廖建;鄭裕明;鄧洪;曾毅;;EBV 4型IgA/VCA IgA/EA IgG/EA IgG/ZEBRA抗體在鼻咽癌普查和早期診斷中的應(yīng)用[J];中華實(shí)驗(yàn)和臨床病毒學(xué)雜志;2006年03期
10 馮大鵬;肖建如;;基質(zhì)金屬蛋白酶及其抑制劑與腫瘤的相關(guān)性[J];腫瘤;2009年09期
，本文編號(hào)：2220197
本文鏈接：http://www.sikaile.net/yixuelunwen/yiyaoxuelunwen/2220197.html
最近更新
教材專著
